Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomePreferred Dividend PaymentsProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

PharmaCyte Biotech (PMCB) Operating Expenses (2016 - 2026)

PharmaCyte Biotech (PMCB) has disclosed Operating Expenses for 16 consecutive years, with $1.4 million as the latest value for Q4 2025.

  • On a quarterly basis, Operating Expenses rose 24.41% to $1.4 million in Q4 2025 year-over-year; TTM through Oct 2025 was $4.2 million, a 42.95% decrease, with the full-year FY2025 number at $4.4 million, down 48.62% from a year prior.
  • Operating Expenses was $1.4 million for Q4 2025 at PharmaCyte Biotech, up from $848305.0 in the prior quarter.
  • In the past five years, Operating Expenses ranged from a high of $3.2 million in Q2 2024 to a low of $756847.0 in Q1 2021.
  • A 5-year average of $1.4 million and a median of $1.2 million in 2024 define the central range for Operating Expenses.
  • Peak YoY movement for Operating Expenses: surged 250.52% in 2024, then crashed 67.09% in 2025.
  • PharmaCyte Biotech's Operating Expenses stood at $1.0 million in 2021, then surged by 130.74% to $2.3 million in 2022, then tumbled by 39.21% to $1.4 million in 2023, then decreased by 21.53% to $1.1 million in 2024, then grew by 24.41% to $1.4 million in 2025.
  • Per Business Quant, the three most recent readings for PMCB's Operating Expenses are $1.4 million (Q4 2025), $848305.0 (Q3 2025), and $1.0 million (Q2 2025).